VPAC1 encodes G-protein–coupled receptors expressed on all breast cancer (BC) cells at
the onset of the disease, but not on benign lesions. Our extensive preclinical studies have …

VIP receptors were investigated in breast cancer biopsy specimens. Twenty biopsy
specimens bound 125I‐VIP with high affinity. Also, each of the 20 biopsy specimens had …

The purpose of this study was to assess the feasibility of PET imaging of oncogene VPAC1
receptors overexpressed in human breast cancer cells. Methods: Vasoactive intestinal …

Among US men, prostate cancer (PC) accounts for 29% of all newly diagnosed cancers. A
reliable scintigraphic agent to image PC and its metastatic or recurrent lesions and to …

Despite the great strides made in imaging breast cancer (BC) in humans, the current
imaging modalities miss up to 30% of BC, do not distinguish malignant lesions from benign …

Vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide have high
affinity for VPAC1, VPAC2 and PAC1 receptors overexpressed on human cancer cells. Four …

The effects of a vasoactive intestinal peptide (VIP) receptor antagonist on mammary
carcinogenesis were investigated using the C3 (1) SV40T antigen (ag) mice. Ten μg/day …

The evaluation of peptide receptors in man is relevant to identifying the physiological target
tissues of a given peptide and to selecting diseases with a sufficient receptor overexpression …

The effects of vasoactive intestinal peptide (VIP) on the proliferation of central nervous
system (CNS) and cancer cells were investigated. VIP has important actions during CNS …

Vasoactive intestinal peptide (VIP) is a 28 amino acid neuropeptide with a wide range of
biological activities. Receptors for VIP (VIP-R) are overexpressed in breast cancer, where …